Search

Alvotech SA

Fermé

SecteurSoins de santé

5.85 10.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.79

Max

5.95

Chiffres clés

By Trading Economics

Revenu

-68M

-67M

Ventes

-93K

106M

P/E

Moyenne du Secteur

42.4

56.432

BPA

-0.11

Marge bénéficiaire

-63.175

Employés

1,279

EBITDA

-54M

-1.5M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+19.25% upside

Dividendes

By Acuity

Prochains Résultats

11 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

461M

1.8B

Ouverture précédente

-4.53

Clôture précédente

5.85

Sentiment de l'Actualité

By Acuity

51%

49%

250 / 339 Classement par Healthcare

Alvotech SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 sept. 2026, 23:01 UTC

Alvotech SA is trading higher in after-market hours, maintaining a position significantly above its 20-day moving average after four consecutive sessions of gains.

17 sept. 2026, 22:11 UTC

Alvotech SA is advancing in after-market trading, continuing its upward trend and remaining well above its 20-day moving average.

16 sept. 2026, 23:01 UTC

Alvotech SA is trading higher in after-market hours, remaining above its 20-day moving average despite a notable decline from an early session high.

14 sept. 2026, 20:08 UTC

Alvotech SA shares are lower today, continuing a decline that began earlier in the session, reversing recent gains from the past three days.

11 sept. 2026, 19:36 UTC

Alvotech SA shares are higher, reflecting intraday strength amid broader market dynamics, including U.S. Consumer Price Index data influencing inflation expectations.

10 sept. 2026, 20:07 UTC

Alvotech SA shares are higher as the European Central Bank raised interest rates by 25 basis points, influencing market dynamics. No specific company news was identified.

9 sept. 2026, 20:07 UTC

Alvotech SA shares are lower today, marking a fourth consecutive decline. The broader market faces pressure from rising crude oil prices above $100 per barrel.

8 sept. 2026, 20:03 UTC

Alvotech SA shares are lower today, having declined since Friday's close. The stock reached a session low before partially recovering.

3 sept. 2026, 19:56 UTC

Alvotech SA shares are trading roughly flat, with no specific news identified. The stock remains significantly above its 20-day moving average.

2 sept. 2026, 21:02 UTC

Alvotech SA shares are lower in after-market hours, continuing recent downward momentum amid a disappointing ADP report on slower job growth.

1 sept. 2026, 20:08 UTC

Alvotech SA shares are trading lower amid broader market trends. Rising oil prices and inflation concerns are influencing market expectations for interest rate hikes.

31 août 2026, 20:03 UTC

Social Media
News

Alvotech SA shares are higher after the FDA accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio.

28 août 2026, 20:07 UTC

News

Alvotech SA shares are rising after Bank of America initiated coverage with a Buy rating and a $7 price target.

26 août 2026, 19:51 UTC

Alvotech SA shares are lower today amid broader market pressures. Inflationary concerns from recent PCE data may influence Federal Reserve policy discussions.

25 août 2026, 19:16 UTC

Alvotech SA shares are lower today after a morning peak. No specific news has been identified to explain the price movement.

24 août 2026, 23:16 UTC

Alvotech SA shares are trading roughly flat in after-market hours. The stock has gained significantly over the past month, remaining above its 20-day moving average.

21 août 2026, 19:51 UTC

News
Social Media

Alvotech SA has signed a licensing agreement with Lotus Pharmaceutical for two biosimilars, potentially generating $150 million in payments, as shares trade higher.

20 août 2026, 20:02 UTC

News

Alvotech reaffirms 2026 revenue guidance amid Q2 revenue decline.

19 août 2026, 23:01 UTC

Event
News

Alvotech SA reaffirmed its 2026 sales guidance of $650 million to $700 million, boosting investor sentiment and driving shares higher in after-market trading.

18 août 2026, 19:16 UTC

Alvotech SA shares are higher today, maintaining a cumulative gain since Monday. The stock is above its 20-day moving average and near its one-month high.

17 août 2026, 21:02 UTC

Alvotech SA shares rose during after-market hours, reaching a high of 2.84%. The price is above its 20-day moving average and near a one-month high.

14 août 2026, 19:56 UTC

Alvotech SA shares are trading roughly flat amid broader market sentiment influenced by a decline in U.S. retail sales for July.

13 août 2026, 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

12 août 2026, 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

11 août 2026, 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

10 août 2026, 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

6 août 2026, 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

5 août 2026, 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

4 août 2026, 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

3 août 2026, 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

Comparaison

Variation de prix

Alvotech SA prévision

Objectif de Prix

By TipRanks

19.25% hausse

Prévisions sur 12 Mois

Moyen 7 USD  19.25%

Haut 8 USD

Bas 6 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

250 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.